SCHEMBL6401783

SCHEMBL6401783

CS(=O)(=O)Nc1ccc(S(N)(=O)=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 12/20 1.00
CA1 P00915 11/20 1.00
CA12 O43570 7/20 1.00
CA9 Q16790 7/20 1.00
CA4 P22748 1/20 0.59
CA6 P23280 1/20 0.59
CA5A P35218 1/20 0.59
CA7 P43166 1/20 0.59
CA14 Q9ULX7 1/20 0.59
CA5B Q9Y2D0 1/20 0.59
HTT P42858 2/20 0.58
ALDH1A1 P00352 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
MAPT P10636 1/20 0.56
CYP2C9 P11712 1/20 0.56
MAPK8 P45983 1/20 0.56
MAPK10 P53779 1/20 0.56
KEAP1 Q14145 1/20 0.56
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12054668 0.83 KEAP1 (0.75) CA2CA1CA12CA9HTT
SCHEMBL28472964 0.82 CA2 (1.00) CA2CA1CA12CA9CA4
SCHEMBL28014642 0.82 CA12 (0.69) CA2CA1CA12CA9HTT
SCHEMBL5284646 0.79 CA2 (0.66) CA2CA1CA12CA9CA4
SCHEMBL8415404 0.78 CA12 (0.64) CA2CA1CA12CA9HTT
SCHEMBL6401779 0.78 CA12 (0.64) CA2CA1CA12CA9HTT
SCHEMBL6839436 0.78 CA12 (0.64) CA2CA1CA12CA9HTT
SCHEMBL29080913 0.78 CA2 (0.69) CA2CA1CA12CA9CA4
SCHEMBL21104560 0.78 CA2 (0.63) CA2CA1CA12CA9CA4
SCHEMBL3521509 0.77 CA2 (1.00) CA2CA1CA12CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1520324-A Antiangiogenic combination thereapy for treatment of cancer 2004-08-11 CN claimed
CN-118831076-A Cannabinoid acid ester compositions and uses thereof EPM (IP)公司 2024-10-25 CN disclosed
CN-113840598-B Cannabinoid acid ester compositions and uses thereof EPM (IP)公司 2024-07-05 CN disclosed
EP-1928925-B1 CROSSLINKED POLYMERS WITH AMINE BINDING GROUPS 3M INNOVATIVE PROPERTIES CO (US) 2010-03-03 EP disclosed
US-7671154-B2 Crosslinked polymers with amine binding groups 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-03-02 US disclosed
US-7671154-B2 Crosslinked polymers with amine binding groups 3M INNOVATIVE PROPERTIES COMPANY (US) 2010-03-02 US disclosed
US-20090215996-A1 CROSSLINKED POLYMERS WITH AMINE BINDING GROUPS 3M INNOVATIVE PROPERTIES COMPANY 2009-08-27 US disclosed
US-20090215996-A1 CROSSLINKED POLYMERS WITH AMINE BINDING GROUPS 3M INNOVATIVE PROPERTIES COMPANY 2009-08-27 US disclosed
US-7544755-B2 Crosslinked polymers with amine binding groups 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-06-09 US disclosed
US-7544755-B2 Crosslinked polymers with amine binding groups 3M INNOVATIVE PROPERTIES COMPANY (US) 2009-06-09 US disclosed
US-20070078243-A1 Crosslinked polymers with amine binding groups 3M INNOVATIVE PROPERTIES COMPANY 2007-04-05 US disclosed
US-20070078243-A1 Crosslinked polymers with amine binding groups 3M INNOVATIVE PROPERTIES COMPANY 2007-04-05 US disclosed
US-20050130251-A1 Reagent for determination of hydrogen peroxide KYOWA MEDEX CO., LTD. (JP) 2005-06-16 US disclosed
CN-1520324-A Antiangiogenic combination thereapy for treatment of cancer 2004-08-11 CN disclosed
EP-1424554-A1 REAGENT FOR DETERMINING HYDROGEN PEROXIDE KYOWA MEDEX CO., LTD. (JP) 2004-06-02 EP disclosed
CN-1134410-C Amine derivatives, process for their preparation and their use as antiarrhythmic agents �й�ʯ����������ʯ�ͻ����������ι� 2004-01-14 CN disclosed
CN-1169141-A Novel amine derivatives, process for their preparation and their use as antiarrhythmic agents C & C RESEARCH LABS (KR) 1997-12-31 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215996-A1 CROSSLINKED POLYMERS WITH AMINE BINDING GROUPS PAM, MSN, PARG CA2 4183/4885CA1 2997/4885CA12 2789/4885
US-20070078243-A1 Crosslinked polymers with amine binding groups PAM, MSN, PARG CA2 4183/4885CA1 2997/4885CA12 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.